Hepatology Impact Factor

The first signal is that Hepatology remains one of the central owner journals for liver disease and liver biology.

The second signal is normalized strength. A JCI of 3.18 is strong, which means the journal is performing well above category average after normalization rather than simply benefiting from a high-citation field.

The third signal is durability. The five-year JIF of 14.5 is close to the current JIF, and the JIF without self-cites is 15.2, which suggests the number is persistent and clean.

The Scopus impact score of 9.55, SJR of 5.557, and h-index of 415 reinforce that Hepatology has deep long-run authority, not just a good recent cycle.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is up from 7.92 in 2023 to 9.55 in 2024. That matters because it suggests Hepatology has regained strength after a softer year and remains one of the most durable liver journals by long-run citation profile.

The overall pattern reads as stable field ownership with renewed upward movement.

The common mistake is to see a strong impact factor and assume any liver-related manuscript should be aimed here.

That is not how Hepatology usually screens. Editors are typically asking:

• is this truly a liver-owned biological or clinical question
• is the model system strong enough for the liver claim
• does the manuscript carry real hepatology consequence
• is the paper better owned by a broader GI journal or a narrower liver venue

The official AASLD and Wiley author materials matter here because they frame Hepatology as a flagship liver journal rather than a general translational medicine venue. That is why weak liver specificity, thin primary validation, or indirect clinical consequence get exposed quickly despite the journal's broad scientific range.

That means the metric confirms journal stature. It does not make a weakly liver-specific paper fit.

In our pre-submission review work on manuscripts targeting Hepatology, the repeat problem is liver relevance that sounds stronger in the cover letter than it does in the evidence package.

Many papers touch the liver. Fewer are genuinely hepatology-owned.

In our pre-submission review work on manuscripts targeting Hepatology, four failure patterns recur.

The paper uses liver as a convenient model. This is common when the biology is general but the authors want the prestige of a liver journal.

Validation is too thin for the claim. Cell-line-only or lightly validated mechanistic stories often struggle here.

The biomarker story is correlation-heavy. Editors usually want more biological explanation than pure association.

The clinical payoff is too indirect. The manuscript may be interesting, but it still does not tell hepatologists what changes.

If that sounds familiar, a Hepatology submission readiness check is usually more useful than another round of polishing.

The impact factor does not tell you whether the liver-specificity is strong enough, whether the model system is convincing enough, or whether the clinical hepatology consequence is visible enough for this editorial bar.

That is where many submissions fail. The metric confirms that Hepatology is strong. It does not prove the manuscript is hepatology-owned.